Davidson Kempner Capital Management LP Decreases Position in AEON Biopharma, Inc. (NASDAQ:AEON)

Davidson Kempner Capital Management LP reduced its stake in AEON Biopharma, Inc. (NASDAQ:AEON) by 75.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 90,053 shares of the company’s stock after selling 276,618 shares during the period. Davidson Kempner Capital Management LP owned 0.23% of AEON Biopharma worth $95,000 as of its most recent SEC filing.

Separately, Vanguard Group Inc. boosted its holdings in shares of AEON Biopharma by 261.8% in the 1st quarter. Vanguard Group Inc. now owns 758,992 shares of the company’s stock valued at $8,804,000 after buying an additional 549,207 shares in the last quarter. 22.78% of the stock is owned by institutional investors and hedge funds.

AEON Biopharma Price Performance

AEON Biopharma stock opened at $0.69 on Monday. AEON Biopharma, Inc. has a fifty-two week low of $0.64 and a fifty-two week high of $17.17. The stock has a 50-day simple moving average of $1.29 and a 200-day simple moving average of $3.53.

AEON Biopharma (NASDAQ:AEON) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.03. On average, research analysts anticipate that AEON Biopharma, Inc. will post -0.77 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright cut their price target on shares of AEON Biopharma from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th.

AEON Biopharma Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.